107 related articles for article (PubMed ID: 1771809)
1. [Chronic active surface-positive Campylobacter antrum gastritis-- morphological changes 1 year after treatment with bismuth].
Sorf M; Krislo V; Gogora M
Vnitr Lek; 1991; 37(9-10):768-71. PubMed ID: 1771809
[TBL] [Abstract][Full Text] [Related]
2. [Morphologic changes in chronic active superficial Campylobacter pylori-positive antrum gastritis after treatment with bismuth].
Sorf M; Krislo V; Gogora M; Masek O
Vnitr Lek; 1990 Aug; 36(8):759-62. PubMed ID: 2136460
[TBL] [Abstract][Full Text] [Related]
3. [Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis].
Malfertheiner P; Stanescu A; Baczako K; Vanek E; Bode G; Ditschuneit H
Dtsch Med Wochenschr; 1988 Jun; 113(23):923-9. PubMed ID: 3378501
[TBL] [Abstract][Full Text] [Related]
4. Is there any relationship between functional dyspepsia and chronic gastritis associated with Helicobacter pylori infection?
Kyzekové J; Arlt J; Arltová M
Hepatogastroenterology; 2001; 48(38):594-602. PubMed ID: 11379362
[TBL] [Abstract][Full Text] [Related]
5. [Effect of eradication treatment on histological changes of the gastric mucosa in patients with non-ulcer dyspesia and Helicobacter pylori infection. Randomized prospective study].
Kyzeková J
Vnitr Lek; 1999 Feb; 45(2):90-6. PubMed ID: 15641227
[TBL] [Abstract][Full Text] [Related]
6. Campylobacter pylori in patients with dyspeptic symptoms and endoscopic evidence of erosion(s).
Elta GH; Murphy R; Behler EM; Barnett JL; Nostrant TT; Kern S; Appelman H
Am J Gastroenterol; 1989 Jun; 84(6):643-6. PubMed ID: 2729235
[TBL] [Abstract][Full Text] [Related]
7. [Campylobacter pylori--relation to gastric pathology and the effect of bismuth therapy].
Huslarová A; Fric P; Jirásek A
Sb Lek; 1990; 92(11-12):349-53. PubMed ID: 2136429
[TBL] [Abstract][Full Text] [Related]
8. [The assessment of nitric oxide metabolites in gastric juice in Helicobacter pylori infected subjects in compliance with grade of inflammatory lesions in gastric mucosa].
Walecka-Kapica E; Knopik-Dabrowicz A; Klupińska G; Chojnacki J
Pol Merkur Lekarski; 2008 Feb; 24(140):95-100. PubMed ID: 18634262
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
Koskenpato J; Färkkilä M; Sipponen P
Scand J Gastroenterol; 2002 Jul; 37(7):778-84. PubMed ID: 12190090
[TBL] [Abstract][Full Text] [Related]
10. [Course of histological lesions of the gastric mucosa after eradication of H. pylori in patients with duodenal ulcer. Initial study and 6-month follow-up].
Gisbert JP; Boixeda D; Alvarez Baleriola I; Redondo C; De Rafael L; Martín de Argila C; Hernández Ranz F
Rev Esp Enferm Dig; 1995 Apr; 87(4):281-7. PubMed ID: 7794634
[TBL] [Abstract][Full Text] [Related]
11. [Bismuth aluminate in gastroenterology. Therapeutic effects in chronic erosive Campylobacter pylori-associated gastritis].
Stanescu A; Malfertheiner P; Mayer D; Baczako K; Ditschuneit H
Fortschr Med; 1989 Oct; 107(29):623-6. PubMed ID: 2680842
[TBL] [Abstract][Full Text] [Related]
12. [Gastric mucosa lesions in gastric ulcer disease. Initial study and 1-year follow-up after Helicobacter pylori eradication].
Bermejo F; Boixeda D; Gisbert JP; Sanz JM; Defarges V; Alvarez Calatayud G; Martín de Argila C
Gastroenterol Hepatol; 2000; 23(6):269-74. PubMed ID: 15324621
[TBL] [Abstract][Full Text] [Related]
13. [Does Campylobacter Helicobacter pylori infection have a clinical relevance? Methodologic, epidemiologic and clinical studies].
Döbrönte Z; Lakatos F; Brittig F; Löcsei Z; Varga L
Gastroenterol J; 1990; 50(1):32-7. PubMed ID: 2390166
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
Morris A; Brown P; Ali MR; Lane M; Palmer R
N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
[TBL] [Abstract][Full Text] [Related]
15. [Is Campylobacter pylori the pathogenic agent in gastritis and peptic ulcer?].
Vráblik V; Trupl J; Pavlovic M; Horváth A; Nespor V
Vnitr Lek; 1989 Jul; 35(7):672-8. PubMed ID: 2800373
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and D cells in patients with gastritis in the course of Helicobacter pylori eradication: a six-month, follow-up study.
Milutinovic AS; Todorovic V; Milosavljevic T; Micev M; Spuran M; Drndarevic N
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):755-66. PubMed ID: 12811306
[TBL] [Abstract][Full Text] [Related]
17. [Electron microscopic findings during treatment of Campylobacter pylori-positive gastritis with bismuth salts].
Rauws EA; Tytgat GN
Z Gastroenterol; 1987 Sep; 25 Suppl 4():41-3. PubMed ID: 3687150
[No Abstract] [Full Text] [Related]
18. Non-ulcer dyspepsia and Helicobacter pylori infection--morphological analysis according to the Sydney system--changes before and after treatment.
Lewy-Trenda I; Trenda P; Wierzchniewska A
Pol J Pathol; 1996; 47(2):57-63. PubMed ID: 8854727
[TBL] [Abstract][Full Text] [Related]
19. [Has Campylobacter pylori infection any clinical relevance? Methodologic, epidemiologic and clinical studies].
Döbrönte Z; Lakatos F; Brittig F; Löcsei Z; Bokor N; Stöckert A; Varga L
Orv Hetil; 1989 Nov; 130(48):2563-8. PubMed ID: 2689946
[TBL] [Abstract][Full Text] [Related]
20. [Chronic gastritis associated to Helicobacter pylori in patients with non-ulcerating dyspepsia and with duodenal ulcer].
Magalhães AF; Almeida JR; Guerrazzi F; Yamanaka A; Mesquita MA; Trevisan MA; Ulson CM
Rev Paul Med; 1991; 109(5):197-203. PubMed ID: 1821064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
